Kelly Shi
Stock Analyst at Jefferies
(1.47)
# 3,210
Out of 4,784 analysts
27
Total ratings
36%
Success rate
-7.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelly Shi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OPT Opthea | Downgrades: Underperform | $1 | $3.41 | -70.67% | 1 | Mar 25, 2025 | |
| TIL Instil Bio | Upgrades: Buy | $11 → $52 | $18.08 | +187.61% | 2 | Jan 7, 2025 | |
| FHTX Foghorn Therapeutics | Maintains: Buy | $18 → $14 | $3.52 | +297.73% | 2 | Dec 16, 2024 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $13 → $19 | $14.59 | +30.23% | 2 | Sep 11, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $174 → $196 | $154.68 | +26.71% | 2 | Aug 13, 2024 | |
| ARTV Artiva Biotherapeutics | Initiates: Buy | $21 | $3.16 | +564.56% | 1 | Aug 13, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $37 | $13.18 | +180.73% | 1 | Jun 28, 2024 | |
| PROK ProKidney | Maintains: Buy | $15 → $6 | $0.91 | +559.34% | 2 | Jun 10, 2024 | |
| PTCT PTC Therapeutics | Maintains: Buy | $35 → $46 | $54.24 | -15.19% | 3 | May 20, 2024 | |
| INCY Incyte | Initiates: Buy | $81 | $60.60 | +33.66% | 1 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $18.95 | +84.70% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $1.55 | +2,222.58% | 1 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $39.86 | -59.86% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $29.62 | +35.04% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $5.10 | +292.16% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $3.14 | +154.78% | 1 | Aug 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $0.83 | +3,152.23% | 1 | Mar 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $52 | $15.25 | +240.98% | 1 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $0.68 | +3,870.59% | 1 | Apr 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.56 | +2,022.19% | 1 | Mar 8, 2021 |
Opthea
Mar 25, 2025
Downgrades: Underperform
Price Target: $1
Current: $3.41
Upside: -70.67%
Instil Bio
Jan 7, 2025
Upgrades: Buy
Price Target: $11 → $52
Current: $18.08
Upside: +187.61%
Foghorn Therapeutics
Dec 16, 2024
Maintains: Buy
Price Target: $18 → $14
Current: $3.52
Upside: +297.73%
Centessa Pharmaceuticals
Sep 11, 2024
Maintains: Buy
Price Target: $13 → $19
Current: $14.59
Upside: +30.23%
Ascendis Pharma
Aug 13, 2024
Maintains: Buy
Price Target: $174 → $196
Current: $154.68
Upside: +26.71%
Artiva Biotherapeutics
Aug 13, 2024
Initiates: Buy
Price Target: $21
Current: $3.16
Upside: +564.56%
Syndax Pharmaceuticals
Jun 28, 2024
Initiates: Buy
Price Target: $37
Current: $13.18
Upside: +180.73%
ProKidney
Jun 10, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $0.91
Upside: +559.34%
PTC Therapeutics
May 20, 2024
Maintains: Buy
Price Target: $35 → $46
Current: $54.24
Upside: -15.19%
Incyte
Feb 23, 2024
Initiates: Buy
Price Target: $81
Current: $60.60
Upside: +33.66%
Feb 20, 2024
Initiates: Buy
Price Target: $35
Current: $18.95
Upside: +84.70%
Feb 5, 2024
Initiates: Buy
Price Target: $36
Current: $1.55
Upside: +2,222.58%
Nov 11, 2022
Initiates: Buy
Price Target: $16
Current: $39.86
Upside: -59.86%
Aug 15, 2022
Initiates: Buy
Price Target: $40
Current: $29.62
Upside: +35.04%
Aug 15, 2022
Initiates: Buy
Price Target: $20
Current: $5.10
Upside: +292.16%
Aug 3, 2022
Initiates: Buy
Price Target: $8
Current: $3.14
Upside: +154.78%
Mar 4, 2022
Initiates: Buy
Price Target: $27
Current: $0.83
Upside: +3,152.23%
Aug 3, 2021
Initiates: Buy
Price Target: $52
Current: $15.25
Upside: +240.98%
Apr 13, 2021
Initiates: Buy
Price Target: $27
Current: $0.68
Upside: +3,870.59%
Mar 8, 2021
Initiates: Buy
Price Target: $33
Current: $1.56
Upside: +2,022.19%